Table 4. Clinical response 10 weeks after initiation of the treatment.

	No response	Partial improvement	Complete healing	Total
ILMA* (% [95% CI])	17 (42.5 [28.5–57.8])	7 (17.5 [8.8–32.0])	16 (40.0 [26.4–55.4])	40 (100)
ILMA + non-silver dressing (% [95% CI])	25 (55.6 [41.2–69.1])	1 (2.2 [0.04–11.6])	19 (42.2 [29.0–56.7])	45 (100)
ILMA + silver dressing (% [95% CI])	27 (49.1 [36.4–61.9])	8 (14.5 [7.6–26.2])	20 (36.4 [24.9–49.6])	55 (100)
Total (%[95% CI])	69 (49.3 [41.1–57.5])	16 (11.4 [7.2–17.8])	55 (39.3 [31.6–47.6])	140 (100)

ILMA  =  intralesioinal meglumine antimoniate. † 95% Confidence Interval.